Abstract Title:

Interstitial lung disease with pleural effusion caused by simvastin.

Abstract Source:

J Intern Med. 1996 Apr ;239(4):361-3. PMID: 8774391

Abstract Author(s):

R E De Groot, L N Willems, J H Dijkman

Article Affiliation:

Department of Pulmonology, Leiden University Hospital, The Netherlands.


Simvastin, a HMG-CoA reductase blocker, is used for the treatment of certain forms of hypercholesterolaemia. Simvastin is prescribed to lower high serum levels of cholesterol by inhibiting a specific enzyme, hydroxy-methylglutarylCo-enzym-A (HMG-CoA) reductase. This ultimately leads to an increase of the number of LDL-receptors in the liver, and thus, to a decrease of the serum LDL-cholesterol. To a much lesser extent it lowers the serum VLDL-cholesterol and makes the serum HDL-cholesterol level rise. In general, this relatively new compound is well tolerated and only a few, mostly minor, adverse effects have been reported so far. We present a patient who developed interstitial lung disease with pleural effusion most probably as a result of the use of Simvastin.

Study Type : Human: Case Report

Print Options

Key Research Topics

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2021 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.